Display Settings:

Format

Send to:

Choose Destination
    Clin Infect Dis. 2006 Oct 1;43(7):904-10. Epub 2006 Aug 23.

    Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.

    Source

    Stanford University Division of Infectious Diseases, USA. vlevy@stanford.edu

    Erratum in

    • Clin Infect Dis. 2006 Nov 15;43(10):1376.

    Abstract

    Coinfections with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are common globally. HIV infection modifies the course of HBV infection by increasing rates of chronicity, prolonging HBV viremia, and increasing liver-related morbidity. To minimize the emergence of HIV and/or HBV resistance, as well as the emergence of liver enzyme flares, the treatment of both infections should be coordinated. Lamivudine or emtricitabine monotherapy readily selects resistant strains in the YMDD motif of the polymerase gene. Adefovir and tenofovir are fully active in the presence of YMDD mutations [corrected] If HBV treatment can be deferred until combination antiretroviral therapy for HIV infection is needed, the combination of tenofovir plus lamivudine or emtricitabine provides potent HBV therapy and a solid backbone for HIV combination antiretroviral therapy, and it likely decreases the emergence of HBV resistance.

    PMID:
    16941375
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk